These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12170180)

  • 1. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
    Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
    Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
    Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
    J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
    Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
    Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
    Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
    Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
    Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
    Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
    Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
    Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
    Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
    Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
    Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
    Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
    Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
    Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
    Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma.
    Hasegawa M; Takata M; Hatta N; Wakamatsu K; Ito S; Takehara K
    Melanoma Res; 1997 Jun; 7(3):243-51. PubMed ID: 9195564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
    Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
    Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
    Klimek VM; Williams L; Chapman PB
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
    Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
    Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
    Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW
    Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
    Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
    Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.